Patient preference for early onset of efficacy of preventive migraine treatments.

ABSTRACT:

Objective

The objective of this study was to ascertain to what extent adults with migraine value an early onset of efficacy for preventive migraine treatments.

Background

In placebo-controlled clinical trials, treatment with eptinezumab resulted in a lower proportion of adults with migraine on the first day following infusion (day 1; 14% point-reduction for chronic migraine [CM] in PROMISE-2 and 8% point-reduction for episodic migraine [EM] in PROMISE-1).

Methods

Adults with migraine completed an online preference-elicitation thresholding exercise to ascertain to what extent they value not having a migraine on day 1 postdosing relative to a clinically relevant reduction in number of migraine days during the first month postdosing (≥2 migraine-free days for CM and ≥1 m

SUBMITTER: Ailani J 

PROVIDER: S-EPMC9306969 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature